Anika Therapeutics Inc.

Anika Therapeutics develops and commercializes products based on hyaluronic acid technology. They offer OA pain management products like Monovisc, Orthovisc, and Cingal for osteoarthritis relief. The company also has a joint preservation and restoration product family including Hyalofast, Tactoset, and others. Additionally, they have non-orthopedic products such as veterinary, anti-adhesion barrier, burn treatment, and ophthalmic products. Founded in 1983, the company is headquartered in Bedford, Massachusetts.

Overview

Sector

Pharmaceutical

Target Price

0.0 USD

Current Price

9.7 USD

Potential

-100%

Strengths

Price to book ratio (0.91) is lower than the sector mean (733.70).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (3.00%) is significantly lower than the sector mean (14.71%).
The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
EBITDA Margin (2.52%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	36.4
Price/Free Cash Flow'	100.0
ROIC	3.0%
Net Debt/EBITDA	100.0

Anika Therapeutics Inc.

Overview

Strengths

Weaknesses

Key Financial Data